Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
Total Revenue Increased 112% to $155 Million in First Quarter 2020 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for
View HTML
Toggle Summary Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2020 financial results and provide an operational update
View HTML
Toggle Summary Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update
DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with management on Monday, April 13, 2020, at 4:30 p.m. ET to discuss the company's preliminary first quarter 2020 financial results and
View HTML
Toggle Summary Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
DUBLIN, Ireland and BRIDGEWATER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), hosted a webcast yesterday to discuss important data with study authors who presented at the American College of Cardiology’s 69 th Annual Scientific Session Together With World Congress
View HTML
Toggle Summary Amarin Comments on Ruling in VASCEPA® ANDA Litigation
DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today commented on the United States District Court for the District of Nevada’s ruling in favor of the generic companies in the company’s patent litigation against two filers of
View HTML
Toggle Summary Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes
Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA  High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality Amarin to Webcast Discussion of Presented Data March 30, 5:30 - 6:30 p.m.,
View HTML
Toggle Summary Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented at the American College of Cardiology’s 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC), Mar
Amarin to Webcast Discussion of Presented Data March 30, 4:30 - 5:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that eight presentations, including one Late-Breaking Science presentation and
View HTML
Toggle Summary Amarin Takes Proactive Steps to Support Public Health Priorities
DUBLIN, Ireland and BRIDGEWATER, N.J., March 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a leader in preventative cardiovascular risk reduction therapy, today announced actions in support of public health initiatives to combat the COVID-19 pandemic.
View HTML
Toggle Summary Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019   Launch Commenced of VASCEPA ® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb.
View HTML
Toggle Summary Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at two upcoming investor conferences. Mr.
View HTML

Amarin Corporation